This retrospective study presents data from 105 consecutive multiple myeloma and lymphoma patients who had PB CD34+ cell counts o 10/μL on day 4 of steady-state G-CSF mobilization for autologous hematopoietic cell transplantation. Our results confirm the capacity of plerixafor to improve mobilization outcomes in this clinical setting. In addition, they show that the effectiveness of plerixafor, compared with G-CSF only, translates to patients with very low (o 3.5/μL) circulating CD34+ cell counts: overnight CD34+ cell count expansion (5.3-vs 1.7-fold), overall CD34+ cell yield (2.29 vs 0.15 × 10 6 CD34+ cells per kg) and patients yielding ⩾ 2 × 10 6 CD34+ cells per kg (63% vs 3%). Furthermore, our data also show that preemptive plerixafor is significantly more effective and more efficient than in remobilization: CD34+ cell yield in the first apheresis (3.28 vs 2.0 × 10 6 CD34+ cells per kg) and overall (3.73 vs 2.44 × 10 6 CD34+ cells per kg), patients yielding ⩾ 2 × 10 6 CD34+ cells per kg in the first apheresis (85% vs 44%) and overall (92% vs 64%), all this requiring less days and doses of plerixafor treatment (1.08 vs 1.48). These data would advocate using plerixafor as an early preemptive intervention based on day 4 circulating CD34+ counts, including very high-risk patients with very low circulating levels.
INTRODUCTION
High-dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) is a standard of care for patients with lymphoma and multiple myeloma. [1] [2] [3] Currently, autologous HCT performed for these indications are almost universally supported by mobilized PBSCs. 4, 5 Hence, inadequate PBSC mobilization may lead to treatment delays and failures, potentially rendering some patients ineligible for the planned HCT. 6, 7 Therefore, the need for management strategies that identify patients at risk in a timely manner and optimize their treatment algorithms to prevent mobilization failure is imperative.
Several clinical factors have been associated with an increased risk of impaired PBSC mobilization. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, the value of patient characteristics and prior treatment clinical factors to successfully score and accurately predict the risk of poor mobilization is controversial, and recent studies do suggest that they are inaccurate predictors and should not be used to identify candidates for optimized strategies to prevent mobilization failure. 17, 18 At present, the measurement of preapheresis levels of CD34+ cells in PB 7, [19] [20] [21] [22] is the most robust and recommended indicator to identify potential poor mobilizers and efficiently rescue them with novel mobilization strategies, including the use of plerixafor. 23, 24 Plerixafor in combination with steady-state G-CSF mobilization in patients with lymphoma and multiple myeloma has been shown very reproducibly to increase PBSC yields and the number of patients yielding target cell doses, both in first-line mobilization [25] [26] [27] [28] and as remobilization strategy in patients who failed prior mobilization attempts, including those with a variety of high-risk clinical factors. [29] [30] [31] [32] [33] [34] [35] Following drug approval by Food and Drug Administration and European Medicines Agency, several groups developed treatment algorithms to guide the use of plerixafor based on CD34+ cell levels in PB and/or the first apheresis product, in combination with a variety of clinical factors. 19, [36] [37] [38] [39] [40] Some of these studies advocate for early intervention based on PB CD34+ cell counts, in what has led to the emerging concept of preemptive use of plerixafor in poor mobilizers. 30, [41] [42] [43] [44] However, clinical practice is still highly heterogeneous, and controversy in studies and practice remains about key aspects, such as the right cutoff value for intervention with plerixafor, whether the benefit from intervention would also translate to candidates with very low preapheresis PB CD34+ cell levels or the relative efficiency of remobilization strategies vs preemptive intervention in this setting.
PATIENTS AND METHODS
This retrospective study includes patients from six transplant centers affiliated for PBSC collection and processing to the Catalan Blood and Tissues Bank (BST). The study group includes all consecutive autologous HCT candidates for lymphoma and multiple myeloma from these centers between January 2008 and September 2011 who had o10 CD34+ cells per μL in PB on day 4 of steady-state mobilization with 10 μg/kg of subcutaneous G-CSF two times daily. Patients mobilized with chemotherapy were excluded from the study. BST personnel carried out apheresis procedures with common apheresis protocols, including large volume apheresis. CD34+ cell counts in PB and the apheresis products were all performed in the central BST laboratory. Throughout this period, candidates mobilized with steady-state G-CSF had PB CD34+ cell counts checked in the mornings of days 4 and 5 of G-CSF administration an hour after the morning dose of G-CSF. Clinical decisions whether to treat or not with plerixafor were made by the transplant physicians according to their local protocols. Such protocols addressing the use of plerixafor and whether to treat patients at risk preemptively based on PB CD34+ cell counts or upon remobilization following a prior failure changed over the study period depending, among other factors, on the transplant center and access to the drug, initially restricted through the European Compassionate Use Program, and from 2010 available following European Medicines Agency and national approvals. The subgroup of patients treated with plerixafor received the drug according to the prescribing information as a 240 μg/kg subcutaneous injection in the evening of day 4, following 4 full days of G-CSF treatment, 10-12 h before the first planned apheresis, in keeping with the timing explored for safety and efficacy in the registration trials and with the evidence available in poor mobilizers. The minimum target to be able to proceed to a single autologous HCT was 2 × 10 6 /kg CD34+ cells. Patients who failed to reach the target with the first apheresis on day 5 received subsequent doses of G-CSF ± plerixafor for up to a maximum of 3 days of collection, or until clinical decision of mobilization failure.
The primary end point was successful collection of ⩾ 2 × 10 6 CD34+ cells per kg. Secondary end points included other PBSC mobilization efficacy outcomes, overall and with only the first apheresis on day 5, including the total yield of CD34+ cells per kg, CD34+ counts in PB (cells per μL) on days 4 and 5 of mobilization, and days 4-5 CD34+ cell count fold-expansion. Mobilization results were specifically analyzed in patients with very low PB CD34+ counts, arbitrarily selected as those o 3.5 CD34+ cells per μL, in line with the median CD34 PB count in the plerixafor group (see below). Mobilization results were also compared between patients receiving plerixafor during remobilization after one or more previous failures and those receiving preemptive plerixafor based on PB CD34+ counts during a first mobilization attempt. Disease-specific treatment before transplant, conditioning regimens for autologous HCT, supporting care and post transplant follow-up were carried out as per center protocols.
Patients were all adults (418 years of age), and all signed informed consent forms for mobilization, transplantation and data collection, as well as for inclusion in the Compassionate Use Program, when applicable. A purpose-built spreadsheet was generated to perform the analysis by the investigators. Descriptive statistics were used to define patients' characteristics and subsets. Shapiro-Wilk tests were performed to test normal distribution of the data, and group comparisons were performed depending on whether such distribution was normal or not either with paired or independent Student's t-test as appropriate, or with nonparametric Mann-Whitney U-tests, respectively. χ 2 Test or Fisher's exact test, when applicable, were used to compare mobilization outcome between patient groups. Two-tailed P-values o0.05 were considered statistically significant. Statistical analyses were all carried out using SPSS software packages version 17.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
This study presents mobilization outcomes from a group of 105 consecutive candidates to autologous HCT mobilized with steadystate G-CSF who had day 4 PB CD34+ cell levels o 10/μL. Seventynine patients had lymphoma (75%; 68 non-Hodgkin and 11 Hodgkin) and 26 had multiple myeloma (25%). Between January 2008 and September 2011, 38 patients received, in addition to G-CSF, plerixafor in the evening of day 4 (plerixafor group; 36%), and 67 completed mobilization with G-CSF only (G-CSF group; 64%). As described in Table 1 , patient characteristics were similar between both treatment groups, other than previous mobilization history, where 85% of the G-CSF group had no prior mobilization attempts, whereas 66% of the plerixafor group had at least one other previous failed mobilization attempt (P o0.001). Second and subsequent mobilization attempts with plerixafor were not included in this analysis. Baseline PB CD34+ cell levels on day 4 of G-CSF mobilization were also comparable in both treatment groups (Table 2) . Treatment on day 4 of G-CSF with plerixafor, compared with G-CSF alone, significantly expanded the circulating levels of CD34+ cells overnight (4.8-vs 1.8-fold) to day 5 morning levels of 18.4 cells per μL (vs 7.6). As a result of this improved mobilization of CD34+ cells into the PB, patients in the plerixafor group had better PBSC collections than their counterparts in the G-CSF group, with an average yield of 2.88 (vs 1.02) CD34+ cells per kg, and a total of 74% of cases (vs 27%) reaching the end point of ⩾ 2 × 10 6 CD34+ cells per kg for one autologous HCT. As shown in Table 2 , even collection outcomes with only the first apheresis in the plerixafor group were superior to the first apheresis and overall outcomes in the G-CSF group.
We decided to analyze next the performance of plerixafor treatment in a high-risk subgroup of patients with very low circulating CD34+ cells. Median day 4 PB CD34+ cell levels were 3.7/μL for the G-CSF group and 3.5/μL for the plerixafor group. As described in the Materials and methods section, we arbitrarily selected a cutoff level o3.5 CD34+ (vs 3.5-10) cells per μL as an indicator to identify the subset of patients with a particularly high risk of mobilization failure (Table 3 ). There were no significant differences in patient characteristics between these subgroups (Supplementary Table 1 ). The expansion of circulating CD34+ cell counts from days 4 to 5 in plerixafor-treated patients with o 3.5 CD34+ cells per μL and those with 3.5-10 CD34+ cells per μL were comparable (5.30 vs 4.21). As expected though, circulating CD34+ cell counts in the morning of day 5 were significantly lower in patients starting on day 4 from very low CD34+ cell counts o 3.5/ μL (12.03 vs 25.09), and PBSC collection outcomes were overall not as good in this very high-risk subset as in patients with 3.5-10 CD34+ cells per μL, with a significantly lower CD34+ cell yield (2.29 vs 3.47 × 10 6 CD34+ cells per kg), and a nonstatistically significant difference in the primary end point of patients reaching the target of ⩾ 2 × 10 6 CD34+ cells per kg (63% vs 84%). Nevertheless, when considering the overall subset of patients with o 3.5 CD34+ cells per μL, all the mobilization outcomes were markedly superior in patients treated with plerixafor than in their CD34+ cells per kg (63% vs 3%). As shown in Table 3 , even after one single first apheresis following plerixafor treatment, collection outcomes were markedly superior to those with G-CSF alone after first apheresis and overall, also in this very high-risk subgroup of patients. To confirm that this finding was not limited to a particular arbitrary cutoff point, we also tested for high-risk subsets of mobilization failure PB CD34+ cell count cutoff levels of o 2 and o 5/μL. Among patients with o2 CD34+ cells per μL on day 4, five out of eight cases in the plerixafor group vs none of 17 cases in the G-CSF-only group reached the primary end point target of 2 × 10 6 /kg (62.5% vs 0%; P o 0.001). Among patients with o5 CD34+ cells per μL on day 4, 17 out of 26 in the plerixafor group vs 7 out of 48 cases in the G-CSF-only group reached the primary end point of 2 × 10 6 /kg (65.3% vs 14.5%; P o0.001). These data confirm that the favorable performance of plerixafor is robust and reproducible in high-risk patients with very low CD34+ cell levels in PB on day 4.
Out of the 38 patients treated with plerixafor, 25 received it as a rescue strategy following at least one previous failed mobilization attempt (remobilization subgroup; 66%), and 13 patients during a first mobilization attempt based on low PB CD34+ cell counts on day 4 (preemptive subgroup; 34%). Patient characteristics other than mobilization history are comparable in these two subgroups (Supplementary Table 2 ). Nevertheless, patients receiving preemptive plerixafor had superior CD34+ cell yields, both overall and in the first apheresis (3.73 and 3.28 × 10 6 CD34+ cells per kg, respectively), compared with patients treated with plerixafor as a remobilization strategy (2.44 and 2.0 × 10 6 CD34+ cells per kg, respectively; Table 4 ). Also, preemptive use led to a higher percentage of patients collecting the target of ⩾ 2 × 10 6 CD34+ cells per kg with only the first apheresis (85% vs 44%). This difference did not reach statistical significance when additional days of treatment and apheresis required to meet the target where considered (92% vs 64%; NS; Table 4 ). As a matter of fact, in addition to the possible differences in mobilization outcomes, the remobilization and preemptive groups showed differences in mobilization efficiency and in the number of plerixafor doses (i.e. days of treatment) required to meet their targets. Within the remobilization group, 16 patients achieved ⩾ 2 × 10 6 CD34+ cells per kg, 11 of them with one single dose of plerixafor and 5 required two doses. Moreover, all nine additional patients in this group received 1 (3 cases), 2 (5 cases) and up to 3 (1 case) days of treatment with plerixafor, despite not reaching the intended Abbreviations: NS, nonsignificant. Note: Comparisons between treatment groups (G-CSF vs G-CSF plus plerixafor) were performed with either Student's t-test or nonparametric Mann-Whitney U-tests, depending on whether or not data followed a normal distribution, and were statistically significant with two-sided P-values o0.001 in all cases but for PB CD34+ cell count on day 4 (NS). Comparisons between treatment groups were performed with either Student's t-test or nonparametric Mann-Whitney U-tests, depending on whether or not data followed a normal distribution. P-values correspond to comparisons between values in central column (plerixafor cases o 3.5 CD34+ cells per μL) and the columns where the P-values are included.
Preemptive plerixafor for very low CD34 counts I Sánchez-Ortega et al target. Conversely, in the preemptive group, only 1 patient failed to yield ⩾ 2 × 10 6 CD34+ cells per kg, having received one dose of plerixafor, and 12 patients did reach the target, 11 with one single dose and 1 with two doses. Thus, patients in the preemptive group required significantly fewer days and doses of plerixafor treatment than patients in the remobilization group in their attempts to yield the target dose (1.08 vs 1.48; P = 0.025). Moreover, our data suggest that preemptive use is even more efficient than remobilization if we consider the total doses per days of treatment with plerixafor in each group in relation to the number of patients who achieved the target ⩾ 2 × 10 6 CD34 + cells per μL for one autologous HCT, with 14 doses for 12 successful mobilizations (1.17), out of 13 patients in the former, and 36 doses for 16 successful mobilizations (2.25), out of 25 patients in the latter (P o 0.001).
DISCUSSION
The arrival of plerixafor has markedly improved the chances of high-risk patients with lymphoma and multiple myeloma to be successfully mobilized for autologous HCT. However, as plerixafor cost is high and the majority of transplant candidates can mobilize adequate PBSC numbers without it, recent efforts focus on treatment strategies that identify patients in whom the benefit of plerixafor can be maximized. Nevertheless, there are still some gaps in our knowledge to efficiently implement plerixafor in such strategies. Our study, with real-life results from six transplant centers using common collection protocols and central laboratory CD34 testing, provides valuable additional information in this area. First, our data confirm in patients with lymphoma and multiple myeloma with o10 CD34+ cells per μL in PB on day 4 of steadystate G-CSF mobilization the evidence available that plerixafor successfully improves mobilization outcomes.
Our analysis provides novel findings suggesting that high-risk patients with very low CD34+ counts in PB (o 3.5/μL) can also be successfully mobilized with plerixafor. Indeed, only one out of 30 such high-risk patients (3%) treated with G-CSF only yielded ⩾ 2 × 10 6 CD34+ cells per kg, whereas 63% of those treated with plerixafor reached the target. Of note, 42% did with a single dose of plerixafor treatment. Prior studies on the performance of plerixafor in patients with low preapheresis PB CD34+ counts have focused on low levels, that is, o 10/μL, 43 failing to address the subset of patients with very low circulating CD34+ cell counts. Lefrère et al. 44 recently showed very interesting data suggesting that the benefit from plerixafor treatment in such very poor mobilizers may further benefit from early monitoring of PB CD34+ cell count and from a specific time course with earlier start of apheresis. Whether such earlier intervention would make the results from patients with o 3.5 cells per μL even better warrants further investigation. While the specific cutoff level to consider such very high-risk population may vary among centers and laboratories, our data suggest that even with the standard 10-12 h overnight administration scheme, patients with very low levels of circulating CD34+ cells at various points from o2 to o 5/μL can benefit from treatment with plerixafor.
Finally, our data also suggest that plerixafor is more effective and more efficient as a preemptive intervention than is remobilization following prior failures. Preemptive plerixafor led to greater CD34+ cell yields, both overall and in the first apheresis, and to a higher percentage of patients reaching the primary end point target of ⩾ 2 × 10 6 CD34+ cells per kg with only the first apheresis (85% vs 44%), and perhaps overall (92% vs 64%). In addition to other considerations on resource use and patient burden related to the number of apheresis, for a high-cost drug such as plerixafor, our data suggest that with remobilization one would need to use 1.5 to 2 times the number of days of plerixafor treatment (i.e. doses), and that even so the outcome might not be as good as with preemptive use, and should have an impact on the development of plerixafor management strategies.
Despite novel findings, our study also has limitations. Patient numbers with PB CD34+ counts o 10/μL on day 4 are too low to extend the analysis to patient subgroups of potential interest, such as comparisons among different underlying diseases. We, and others, have reported the impact of disease type on mobilization with plerixafor in multicenter multinational series. 29, 30, 33 The retrospective design of our study has potential caveats, despite the focus of our results on laboratory tests performed in a single central laboratory with uniform protocols for all cases throughout the study period. On the other hand, transplant centers in the study carry out all their autologous transplant mobilizations, collections and cell processing through the BST, from where the data and list of all consecutive eligible cases for the study were collected, minimizing the risk for selection bias. In addition, although the clinical decisions to intervene with plerixafor changed over time depending on transplant physicians, their local protocols and drug availability, the data generated provide guidance based on real-life practice. Finally, although our findings suggest that preemptive administration of plerixafor is more efficient than remobilization following prior failures, our study can neither provide firm conclusions on this point nor address the cost-effectiveness of plerixafor in comparison with other alternative ways to manage such high-risk patients with low circulating PB CD34+ cell counts.
In summary, our data show that plerixafor significantly improves all the mobilization outcomes of lymphoma and myeloma patients with low circulating CD34+ counts on day 4 of G-CSF steady-state mobilization. Furthermore, they show that plerixafor administration can successfully mobilize the subset of patients with very low CD34+ cell counts in PB and strongly support its use in such high- risk patients. Finally, they suggest that preemptive intervention with plerixafor may be more effective and efficient than in remobilization following prior failures, and that it achieves better mobilization outcomes with less days of plerixafor treatment. These data advocate mobilization strategies that optimize the management through a timely identification of poor mobilizers based on circulating CD34+ cell counts on day 4 of G-CSF, and an early preemptive intervention with plerixafor in patients with low levels, including high-risk patients with very low circulating levels.
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